• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

April 3 Biweekly Strategy Webinar Q&A

Diary, Newsletter

Below please find subscribers’ Q&A for the Mad Hedge Fund Trader April 3 Global Strategy Webinar with my guest and co-host Bill Davis of the Mad Day Trader. Keep those questions coming!

Q: I’ve gotten a lot of newsletters but not many trades. Why is that?

A: Perfect trades do not happen every day of the year. They happen a few times a year and they tend to bunch up. Most time in the market is spent waiting for an entry point and then piling on 5 or 10 trades rapidly. We’re letting our profits run and waiting for new trades to open up, so just be patient and we’ll get you more trades than you can chew on.

If you have to ask this question, you are probably overtrading. The goal is to make yourself rich, not your broker. The other newsletters that offer a trade alert every day don’t publish their performance as I do and lose money for their followers hand over fist.

Q: Are we on track for a market peak in May?

A: Yes; if we keep climbing up, eventually hitting new highs this month, then we are setting up perfectly for a pretty sharp pullback around May 10th. That would be a good time to get rid of all your longs and put on some short positions, certainly deep in the money put spreads—we’ll be knocking quite a few of those out in the end of April/beginning of May.

Q: Are you worried about the Russell 2000 (IWM) climb?

A: I’m not. If you look at the chart, every up move has been weak, and every down move has been strong. Looking at the chart, it’s still in a clear downtrend dragging all the other markets, and this is because small-cap stocks do poorly in recessions or market pullbacks.

Q: How severe and how long do you see the coming bear market being?

A: If history repeats itself, then it’s going to be rather shallow. The last move down was only three months long and that stunned a lot of people who were expecting a more extreme pullback. I don’t see conditions in place that indicate a radically deep pullback—25% at most and 6-12 months in duration, which won’t be enough to liquidate your portfolio and justify the costs of getting out now and trying to get back in later. They key thing is that there are no systemic threats to the market other than the exploding levels of government borrowing.

Q: If you had the Tesla (TSLA) April $310-$330 vertical bear put spread, would you keep it?

A: Probably, yes, because you have a $15 cushion against a good news surprise and a lot less at risk. I got out of my Tesla (TSLA) April $300-$320 vertical bear put spread because my safety cushion shrank to only $5 and the risk/reward turned sharply against me.

Q: Should we be buying the Volatility Index (VIX) here for protection?

A: Not yet; we still have enough momentum in the stock market to hit all-time highs. After that, you really want to start looking at the VIX hard, especially if we get down to the $12 level. So good thinking, just not quite yet—as we know in the market, timing is everything.

Q: Are you getting nervous about the short Disney (DIS) calls?

A: I’m always nervous, every day of the year about every position, and yes, I’m watching them. You are paying me to be nervous so you can go play golf. We may take a small hit on the calls if the stock keeps rising, but that will be offset by a bigger gain on the call spread we’re long against.

Q: When is the quarterly option expiration?

A: It was on March 15 and the next one is June 21. This is an off-month expiration coming up on April 18th, and that’s only 12 trading days away.

Q: If you get a hard Brexit (FXB) in the next few weeks, what will happen to the pound?

A:  It’s risen about 10% in the last few weeks on hopes of a Brexit outright failure. If that doesn't happen, the pound will get absolutely slaughtered.

Q: If China (FXI) is stimulating their economy, will that eventually help the U.S.?

A: Stimulus anywhere in the world always gets back to the U.S. because we’re the world’s largest market. So, yes, it will be positive.

Q: Would you consider trading UK stocks under Brexit fail?

A: Yes, and there is a UK stock ETF, the iShares MSCI United Kingdom ETF(EWU) and you’re looking at a 20%-25% rise in the British stock market if they completely give up on Brexit or just have another election.

 Q: What are your thoughts on the China trade war?

A: The Chinese are in no rush to settle; that’s why we keep missing deadline after deadline and all the positive rumors are coming from the U.S. side. It’s looking more like a photo op trade deal than an actual one.

 Q: If we get a top in stocks in May, how far do you expect (SPY) to go?

A: Not far; maybe 5% or 10%, you just have to allow all the recent players who got in to get out again, and if the economy slows to, say, a 1% rate in Q1, that’s not a panicky type market. That’s a 10% correction market and what we’ll probably get. If the economy then improves in Q2 and Q3, then we may go back up again to new highs. We seem to have a three quarter a year stock market and therefore, a three quarter a year stock market. Q1 is always a write off for the economy.

Q: Do you still like Amazon (AMZN)?

A: Absolutely, yes—it’s going to new highs. And it’s also starting to make a move on the food market, cutting prices at Whole Foods, which it owns, for the 3rd time this year. So, it’s moving on several fronts now, including healthcare. There’s at least a double in the company long term from these levels, and a triple if they break the company up.

Q: If you bought the stock in Boeing (BA) instead of the option spread, would you stay long?

A: I would, yes. It’s a great company and there's an easy 10% move in that stock once they get the 737 MAX back off the ground again which they should do within the month.

Q: What do you think about food stocks with big name brands like Hershey (HSY)?

A: I’ve never really liked the food industry. It’s really a low margin industry. You’re looking at 2% a year earnings growth against the big food companies vs 20% a year growth in tech which is why I stick with tech. My advice is always to focus on the few sectors that are the best 5% of the market and leave the dross for the index funds.

 Q: With the current bullish wave in the market (SPY), what sector/stocks do you think have the most momentum to break out another 10% to 15% gain in the next one to three months?

A: The next 10% to 15% in the market will only happen after we drop 5-10% first. I believe this is the last 5% move of the China trade deal rally and after that, markets will fall or go to sleep for six months.

Q:  Do you expect 2019 to be more like 2018 or 2017? We know you are predicting the (SPX) will hit an all-time high of 3000 in 2019. Do you think it zooms up to a blow-off top in Q2/Q3 and then pulls back in Q4, like 2018?  Or, do you expect a steadier ascent with minor pullbacks along the way (like 2017), closing at or near the year's highs on Dec 31? This guidance will really help.

A: I think we have made most of the gains for 2019. Only the tag ends are lifted. We have already hit the upside targets for most strategists, and mine is only 7% higher. After that, there is a whole lot of boring ahead of us for 2019 and the (VIX) should drop to $9. After complaining about horrendous market volatility in December, traders will beg for volatility.

Good Luck and Good Trading
John Thomas
CEO & Publisher
Diary of a Mad Hedge Fund Trader

 

 

 

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/04/john-thomas.png 281 300 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-05 01:06:132019-07-09 03:56:02April 3 Biweekly Strategy Webinar Q&A
Mad Hedge Fund Trader

April 4, 2019

Diary, Newsletter, Summary

Global Market Comments
April 4, 2019
Fiat Lux

Featured Trade:
(TEN REASONS WHY STOCKS CAN’T SELL OFF BIG TIME),
(SPY)
(SCAM OF THE MONTH CLUB)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-04 01:08:552019-04-03 16:30:34April 4, 2019
Arthur Henry

Scam of the Month Club

Diary, Newsletter

Having trouble raising capital for your new hedge fund?

Just list Warren Buffet as your “Honorary Chairman.”

That’s what California prison guard Ottoniel Medrano did. To help his marketing efforts, he also claimed that he had $4.8 billion in assets under management as well as massive real estate holdings somewhere in Asia.

Medrano’s International Realty Holdings managed to raise $700,000 from individuals with this scam which he promptly shipped to offshore bank accounts before the Feds shut him down.

When you think you’ve heard everything, something like this pops up. Unbelievable.

You would think that people have heard of “due diligence” by now.

People with famous financial names like Morgan, Rockefeller, Rothschild, Getty, and DuPont often find out they are endorsing things they have never heard of to help someone’s fundraising effort.

I once heard of a guy who got a license plate of GETTY 1 just so he could get free valet parking at restaurants.

More recently, president Donald Trump has faced the same problem.

More than 200 companies in China are marketing products under his name without his permission.

After years of languishing in the courts, one judge finally ruled in his favor, the day after the new president affirmed the long-standing ‘One China Policy.”

Who said being Commander in Chief didn’t have its benefits?

It all brings back unpleasant memories of the Bernie Madoff scandal.

By the way, Bernie has only 123 years left on his sentence. By then he will be 201 years old.

Who knows? Maybe on that low-fat, low-carb prison diet, he’ll make it. He has a better health plan than I do.

I’m only on Medicare.


Want to Invest in My Fund?
https://www.madhedgefundtrader.com/wp-content/uploads/2013/03/Bernie-Madoff.jpg 282 354 Arthur Henry https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Arthur Henry2019-04-04 01:06:502019-04-04 01:17:14Scam of the Month Club
Arthur Henry

Quote of the Day - April 4, 2019

Diary, Newsletter, Quote of the Day

"Markets will over value what you can quantify," said Ann Lamont at Oak Investment Partners, referring to the extreme high prices for public companies versus the discount valuations of private ones.

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Arthur Henry https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Arthur Henry2019-04-04 01:05:362019-04-03 16:43:14Quote of the Day - April 4, 2019
Mad Hedge Fund Trader

April 3, 2019

Diary, Newsletter, Summary

Global Market Comments
April 3, 2019
Fiat Lux

Featured Trade:

(WHO WILL BE THE NEXT FANG?)
(FB), (AMZN), (NFLX), (GOOGL), (AAPL),
(BABA), (TSLA), (WMT), (MSFT),
(IBM), (VZ), (T), (CMCSA), (TWX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-03 01:07:522019-04-02 17:50:07April 3, 2019
Arthur Henry

Who Will Be the Next FANG?

Diary, Newsletter

FANGS, FANGS, FANGS! Can’t live with them but can’t live without them either.

I know you’re all dying to get into the next FANG on the ground floor, for to do so means capturing a potential 100-fold return, or more.

I know because I’ve done it four times. The split adjusted average cost of my Apple shares is only 25 cents compared to today’s $174, so you can understand my keen interest. My average on Tesla is $16.50.

Uncover a new FANG and the riches will accrue rapidly. Facebook (FB), Amazon AMZN), Netflix (NFLX), and Alphabet (GOOGL) didn’t exist 25 years ago. Apple (AAPL) is relatively long in the tooth at 40 years. And now all four are in a race to become the world’s first trillion-dollar company.

One thing is certain. The path to FANGdom is shortening. It took Apple four decades to get where it is today, Facebook did it in one. As Steve Jobs used to tell me when he was running both Apple and Pixar, “These overnight successes can take a long time.”

There is also no assurance that once a FANG always a FANG. In my lifetime, I have seen far too many Dow Average components once considered unassailable crash and burn, like Eastman Kodak (KODK), General Electric (GE), General Motors (GM), Sears (SHLD), Bethlehem Steel, and IBM (IBM).

I established in an earlier piece that there are eight essential attributes of a FANG, product differentiation, visionary capital, global reach, likeability, vertical integration, artificial intelligence, accelerant, and geography.

We are really in a “What have you done for me lately” world. That goes for me too. All that said, I shall run through a short list for you of the future FANG candidates we know about today.

Alibaba (BABA)

Alibaba is an amalgamation of the Chinese equivalents of Amazon, PayPal, and Google all sewn together. It accounts for a staggering 63% of all Chinese online commerce and is still growing like crazy. Some 54% of all packages shipped in China originate from Alibaba.

The juggernaut has over half billion active users, and another half billion placing orders through mobile phones. It is a master of AI and B2B commerce. There is nothing else like it in the world.

However, it does have some obvious shortcomings. Its brand is almost unknown in the US. It has a huge problem with fakes sold through their sites.

It also has an ownership structure for foreign investors that is byzantine, to say the least. It is a contractual right to a share of profits funneled through a PO box in the Cayman Island. The SEC is interested, to say the least.

We also don’t know to what extent founder Jack Ma has sold his soul to the Beijing government. It’s probably a lot. That could be a problem if souring trade relations between the US and the Middle Kingdom get worse, a certainty with the current administration.

Tesla (TSLA)

Before you bet on a new startup breaking into the Detroit Big Three, go watch the movie “Tucker” first. Spoiler Alert: It ends in tears.

Still, Tesla (TSLA) has just passed the 270,000 mark in the number of cars manufacturered. Tucker only got to 50.

Having led my readers into the stock after the IPO at $16.50, I am already pretty happy with this company. Owning three of their cars helps too (two totaled). But Tesla still has a long way to go.

It all boils down to the success of the $35,000, 200-mile range Tesla 3 for which it already has 500,000 orders. So far so good.

It’s all about scale. If it can produce these cars in sufficient numbers, it will take over the world and easily become the next FANG. If it can’t, it won’t. It’s that simple.

To say that a lot is already built into the share price would be an understatement. Tesla now trades at ten times revenues compared to 0.5 for Ford (F) and (General Motors (GM). That’s a relative overvaluation of 20:1.

Any of a dozen competing electric car models could scale up with a discount model before they do, such as the similarly priced GM Bolt. But with a ten-year lead in the technology, I doubt it.

It isn’t just cars that will anoint Tesla with FANG sainthood. The firm already has a major presence in rooftop solar cell installation through Solar City, utility sized solar plants, industrial scale battery plants, and is just entering commercial trucks. Consider these all seeds for FANGdom.

One thing is certain. Without Tesla, there wouldn’t be s single mass-market electric car on the road today.

For that, we can already say thanks.

Uber

In the blink of an eye, ride sharing service Uber has become essential for globe-trotting travelers such as myself.

Its 2 million drivers completely disrupted the traditional taxi model for local transportation which remains unchanged since the days of horses and buggies.

That has created the first $75 billion of enterprise value. It’s what’s next that could make the company so interesting.

It is taking the lead in autonomous driving. It could also replace FeDex, UPS, DHL, and the US post office by offering same day deliveries at a fraction of the overnight cost.

It is already doing this now with Uber Foods which offers immediate delivery of takeouts (click here if you want lunch by the time you finish reading this piece.)

UberCopters anyone? Yes, it’s already being offered in France and Brazil.

Uber has the potential to be so much more if it can just outlive its initial growing pains.

It is a classic case of the founder being a terrible manager, as Travis Kalanick has lurched from one controversy to the next. The board finally decided he should spend much time on his new custom built 350-foot boat.

Its “bro” culture is notorious, even in Silicon Valley.

It is also getting enormous pushback from regulators everywhere protecting entrenched local interests. It has lost its license in London, the only place in the world that offered a decent taxi service pre-Uber. Its drivers are getting beaten up in Paris.

However, if it takes advantage of only a few of the doors open to it, status as a FANG beckons.

Walmart (WMT)

A few years ago, I was heavily criticized for pointing out that half the employees at my local Walmart (WMT) were missing their front teeth. They have since received a $2 an hour's pay raise, but the teeth are still missing. They don’t earn enough money to get them fixed.

The company is the epitome of bricks and mortar in a digital world with 12,000 stores in 28 countries. It is the largest private employer in the US, with 1.4 million workers, mostly earning minimum wage.

The Walmart customer is the very definition of the term “late adopter.” Many are there only because unlike Amazon, Wal-Mart accepts cash and Food Stamps.

Still, if Walmart can, in any way, crack the online nut, it would be a turbocharger for growth. It moved in this direction with the acquisition of Jet.com for $3 billion, a cutting-edge e-commerce firm based in Hoboken, NJ.

However, this remains a work in progress. Online sales account for only 4% of Walmart’s total. But they could only be a few good hires at the top away from success.

Microsoft (MSFT)

Talk about going from being the 800-pound gorilla to an 80 pound one, and then back to 800 pounds.

I don’t know why Microsoft (MSFT) lost its way for 15 years, but it did. Blame Bill Gates’s retirement from active management and his replacement by his co-founder Steve Ballmer.

Since Ballmer’s departure in 2014, the performance of the share price has been meteoric, rising by some 125% over the past two years.

You can thank the new CEO Satya Nadella who brought new vitality to the job and has done a complete 180, taking Microsoft belatedly into the cloud.

Microsoft was never one to take lightly. Windows still powers 90% of the world’s PCs. No company can function without its Office suite of applications (Word, Excel, and PowerPoint). SQL Server and Visual Studio are everywhere.

That’s all great if you want to be a public utility, which Microsoft shareholders don’t.

LinkedIn, the social media platform for professionals, could be monetized to a far greater degree. However, specialization does come at the cost of scalability.

It seems that the future is for Microsoft to go head to head against next door neighbor Amazon (AMZN) for the cloud services market while simultaneously duking it out with Alphabet (GOOGL).

My bet is that all three win.

Airbnb

This is another new app that has immeasurably changed my life for the better. Instead of cramming myself into a hotel suite with a wildly overpriced minibar for $600 a night, I get a whole house for $300 anywhere in the world, with a new local best friend along with it.

Overnight, Airbnb has become the world’s largest hotel chain without actually owning a single hotel. At its latest funding round in 2017, it was valued at $31 billion.

The really tricky part here is for the firm to balance out supply and demand in every city in the world at the same time. It is also not a model that lends itself to vertical integration. But who knows? Maybe priority deals with established hotels are to come.

This is another firm that is battling local regulation, that great barrier to technological innovation. None other than its home town of San Francisco now has strict licensing requirements for renters, a 30 day annual limitation, and a $1,000 a day fine for offenders.

The downtowns of many tourist meccas like Florence, Italy and Paris, France have been completely taken over by Airbnb customers, driving rents up and locals out.

IBM (IBM)

There was a time in my life when IBM was so omnipresent we thought like the Great Pyramids of Egypt it would be there forever. How times change. Even Oracle of Omaha Warren Buffet became so discouraged that he recently dumped the last of his entire five-decade long position.

A recent 20 consecutive quarters of declining profits certainly hasn’t helped Big Blue’s case. It is one of the only big technology companies whose share price has gone virtually nowhere for the past two years.

IBM’s problem is that it stuck with hardware for too long. An entrenched bureaucracy delayed its entry into services and the cloud, the highest growth areas of technology.

Still, with some $80 billion in annual revenues, IBM is not to be dismissed. Its brand value is still immense. It still maintains a market capitalization of $144 billion.

And it has a new toy, Watson, the supercomputer named after the company’s founder, which has great promise, but until now has remained largely an advertising ploy.

If IBM can reinvent itself and get back into the game, it has FANG potential. But for the time being, investors are unimpressed and sitting on their hands.

The Big Telecom Companies

My final entrant in the FANGstakes would be any combination of the four top telecommunication companies, Verizon (VZ), AT&T (T), Comcast (CMCSA), and Time Warner (TWX), which now control a near monopoly in the US.

There is a reason why the administration is blocking the AT&T/Time Warner merger, and it is not because these companies are consistently cited in polls as the most despised in America. They are trying to stop the creation of another hostile FANG.

Still, if any of the big four can somehow get together, the consequences would be enormous. Ownership of the pipes through which the modern economy courses bestows great power on these firms.

And Then….

There is one more FANG possibility that I haven’t mentioned. Somewhere, someplace, there is a pimple-faced kid in a dorm room thinking up a brand-new technology or business model that will take the world by storm and create the next FANG.

Call me crazy, but I have been watching this happen for my entire life.

I want to thank my friend, Scott Galloway, of New York University’s Stern School of Business, for some of the concepts in this piece. His book, “The Four” is a must read for the serious tech investor.

 

 

 

 

 

Creating the Next FANG?

https://www.madhedgefundtrader.com/wp-content/uploads/2018/02/tech-guys.jpg 368 550 Arthur Henry https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Arthur Henry2019-04-03 01:06:312019-04-02 17:47:43Who Will Be the Next FANG?
Arthur Henry

Ten Reasons Why Stocks Can't Sell Off Big Time

Diary, Newsletter

While driving back from Lake Tahoe last weekend, I received a call from a dear friend who was in a very foul mood. 

Following the advice of another newsletter whose name I won’t mention, he bailed out of all his stocks during the December meltdown. He was promised that Armageddon was coming, and the Dow would collapse all the way to 3,000. 

With the Federal Reserve now on a rate easing path, here we are with the major stock indexes just 2.7% short of all-time highs.

Why the hell are stocks still going up?

I paused for a moment as a kid driving a souped up Honda weaved into my lane of Interstate 80, cutting me off. Then I gave my friend my response, which I summarize below:

1) There is nothing else to buy. Complain all you want, but US equities are now one of the world’s highest yielding securities, with a lofty 2.0% dividend. 

A staggering 50% of S&P 500 stocks now yield more than US Treasury bonds (TLT). That compares to two thirds of all developed world debt offering negative rates and US Treasuries at a parsimonious 2.48%.

2) Oil prices have bottomed, but remain historically low, and the windfall cost savings are only just being felt around the world. $60 a barrel is a hell of a lot cheaper than $150.

3) While a low Euro (FXE) if definitely eating into large multinational earnings, we are probably approaching the end of the move. The cure for a weak euro is a weak euro. The worst may be behind for US exporters.

4) What follows a collapse in European economic growth? A European recovery powered by a weak currency. European quantitative easing is working.

5) What follows a Japanese economic collapse? A recovery there too, as hyper accelerating QE feeds into the main economy. Japanese stocks are now among the world’s cheapest. 

6) While the next move in interest rates will certainly be up, it is not going to move the needle on corporate P&L’s for a very long time. We might see at most two 25 basis point hikes by the end of this cycle, and that probably won’t happen until the second half of 2019. In a deflationary world, there is no room for more. 

This will make absolutely no difference to the large number of high growth corporates, like technology firms, that don’t borrow at all because they have enormous cash internal flows.

7) Technology everywhere is accelerating at an immeasurable pace, causing profits to do likewise. You see this in the FANG stocks, where blockbuster earnings reports are becoming as reliable as free upgrades. 

Biotech has been on a tear as well.

See the new Alzheimer’s cure? It involves extracting the cells from the brains of alert 95-year old’s, cloning them, and then injecting them into early stage Alzheimer’s patients. I’ve already put myself on the waiting list.

The success rate has been 70%. That one alone could be worth $5 billion a year. I might be a user of this cure myself someday.

8) US companies are still massive buyers of their own stock, some $1 trillion worth this year, and a relaxed repatriation tax law is pouring gasoline on the fire. 

This has created a free put option for investors for the most aggressive companies, like Apple (AAPL), Cisco Systems (CSCO), Microsoft (MSFT), IBM (IBM), and Intel (INTC), the top five re-purchasers. 

They have nothing else to buy either. (AIG) has mandated the repurchase of an amazing 25% of its outstanding float.

They are jacking up dividend payouts at a frenetic pace as well and are expected to return more than $700 billion in payouts this year.
 

9) Ignore this at your peril, but China is stimulating their economy like crazy, and it is just a matter of time before that growth spills over to the US.

10) Ditto for the banks, which were dragged down by falling interest rates for most of the last decade. Reverse that trade this year, and you have another major impetus to drive stock indexes higher.

My friend was somewhat set back, dazzled, and nonplussed by my out of consensus comments. 

With that, I told my friend I had to hang up, as another kid driving a souped up Shelby Cobra GT 500, obviously stolen, was weaving back and forth in front of me requiring my attention.

Where is a cop when you need them?

 

https://www.madhedgefundtrader.com/wp-content/uploads/2018/03/car.jpg 230 438 Arthur Henry https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Arthur Henry2019-04-03 01:06:262019-04-03 11:20:15Ten Reasons Why Stocks Can't Sell Off Big Time
Mad Hedge Fund Trader

April 2, 2019

Diary, Newsletter, Summary

Global Market Comments
April 2, 2019
Fiat Lux

Featured Trade:
(WHAT’S REALLY BEHIND THE BRISTOL MYERS/CELGENE MERGER),
(BMY), (CELG),
(ON EXECUTING MY TRADE ALERTS),

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-02 09:08:032019-04-02 09:20:27April 2, 2019
Mad Hedge Fund Trader

What’s Really Behind the Bristol Myers/Celgene Merger?

Diary, Newsletter

The start of 2019 saw Bristol-Myers Squibb (BMY) reveal a plan that rattled a number of its investors: the 132-year-old biotech giant plans to buy Celgene (CELG) for $74 billion or approximately $102.43 per share.

While these kinds of moves happen often, Bristol’s decision has some of its major shareholders up in arms. So far, Bristol top holder Wellington with 8% of shares, Dodge & Cox with 2.61%, and Starboard Value with 0.06% have publicly expressed their opposition to the merger.

Aside from labeling this deal as “ill-advised,” Starboard suggested that Bristol should either consider selling itself or simply put an end to this plan.

Here’s a short background on the matter.

For Bristol, this deal seemed to have stemmed from the dwindling performance of its mega-blockbuster immuno-oncology drug Opdivo compared to its greatest competitor, Merck & Co’s (MRK) Keytruda.

Unfortunately for Bristol, Opdivo failed to obtain a monotherapy in first-line lung cancer result while Keytruda succeeded on this front. The whole process resulted in costly losses to Bristol and massive sales for Merck in the tune of $7.2 billion, outpacing Opdivo’s $6.7 billion in 2018 – a first for both drugs since the two had been neck to neck since their launches.

The threat of competing cancer drugs – generic and otherwise – against Opdivo didn’t help either. In effect, Bristol has been facing pressure from investors to recoup the costs either via expansion or a profitable merger. By comparison, Bristol’s annual revenue is at $22.6 billion while Merck is at $42.3 billion and fellow competitor Pfizer (PFE) is at $53.4 billion.

On the other side of the merger, Celgene (CELG) has been struggling with the looming loss of its patent protection for their major drug Revlimid, a multiple myeloma medication which accounts for 65% of the company’s $14.2 billion annual revenue. By 2022, generic alternatives are anticipated to eat away the shares of Revlimid. This puts roughly $10 billion in annual sales at risk for Celgene.

In comparison, Celgene’s competitors seem miles ahead based on their reported annual revenues alone, with Eli Lilly (LLY) at $24.6 billion and Novartis (NOVN) at $51 billion.

Celgene’s response to this impending “doom” is to come up with a promising stable of treatments and medications to offset their future losses. This is where Bristol comes in.

While it’s still up in the air if the merger would actually benefit Bristol massively, Celgene seems to be on a win-win situation here. With the money from Bristol, Celgene can relax a bit about the competitors chomping at the bit to decimate Revlimid’s status in the market. On top of that, they’ll be able to insulate themselves (and portfolios) from potential failures in their pipeline.

What about Bristol?

Well, you can look at the merger as Bristol paying for Celgene’s ideas. With a pipeline brimming at the seams, Bristol would be able to have choice picks on what could be their next blockbuster drug especially in light of the weakening performance of Opdivo in the market.

Not only that, another Bristol mega-blockbuster drug Eliquis, an atrial fibrillation medication, is expected to see a decline in sales starting 2022 due to its pending patent expiration.

So far, Bristol shares have experienced a drop by -25.29% or -$17.25, putting it at $50.97 per share in comparison with its previously recorded high of $68.22 last week. The past 52 weeks have also seen Bristol trade as low as $44.3. Meanwhile, its current earnings-per-share (EPS) is estimated to sit at around $1.04 per share.

These estimates make a number of investors bullish with regard to the near-term reports of Bristol a modest prediction of an 11.3% increase in its average price target. This is estimated to lead to a potential market cap rise to $93.04 billion.

How realistic is this promising future of overflowing pipeline for Bristol?

Details of the merger reveal that Celgene will get a contingent value right (CVR) worth a one-time $9-per-share bonus if the company’s three most promising treatments snag FDA approval on set dates: multiple sclerosis drug Ozanimod and Liso-cel by December 31, 2020, as well as bb2121 by March 31, 2021.

Is it achievable?

It looks like it since all three drugs already have available data and are set for late-stage trials necessary for regulatory approvals.

Is this a slam dunk deal then?

This depends greatly on how Celgene works out the kinks of their drugs. So far, Ozanimod was rejected by the FDA in 2018 due to doubts on the company’s capacity to execute the trials effectively. Will Bristol’s backing guarantee approval in the next round? Possibly, especially since the FDA’s rejection was reportedly due to a lack of potential funding by Celgene to support their trials.

Whether or not this deal pushes through heavily depends on the other major shareholders of Bristol. So far, the opposition raised by the three investors hasn’t really resulted in the company wavering on this plan.

However, April 12 is a long way to go when it comes to finalizing this takeover and both sides are still working on persuading their fellow shareholders to stand by their arguments.

What about Celgene? How does this takeover sound to their investors?

Celgene’s investors should be celebrating since this merger has a lot of promising upsides for them and quite frankly, offers a highly lucrative escape plan. Bristol’s buying price of $102.43 per stock is a 54% premium in comparison to the average price of per Celgene share. The CVR incentive offered by Bristol definitely adds the icing to the cake for Celgene investors as well.

Overall, the deal seems to be a reasonable move for both Celgene and Bristol. While the merger definitely has its fair share of risks, Bristol’s key takeaway here is the plethora of opportunities to grow their SKUs. Even with the threat of Celgene’s Revlimid losing patent protection in the years to come, this takeover still offers good strategic positioning shots and promising pipeline expansion for Bristol.

After all, both companies are not necessarily goldmines for investors and are poised to crash sometime soon given their recent performance trends. Perhaps joining forces would give them a fighting chance to ward off more hostile takeovers or worse, a bankruptcy.

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-02 09:07:552019-04-02 09:20:38What’s Really Behind the Bristol Myers/Celgene Merger?
Mad Hedge Fund Trader

April 1, 2019

Diary, Newsletter, Summary

Global Market Comments
April 1, 2019
Fiat Lux

Featured Trade:

(MARKET OUTLOOK FOR THE WEEK AHEAD, OR THE INMATES ARE RUNNING THE ASYLUM)
(SPY), (TLT), (FCX), (DIS), (TSLA), (IWM), (AAPL),
 (GOOGL), (MSFT), (PYPL), (AMZN)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2019-04-01 08:07:292019-04-01 08:12:16April 1, 2019
Page 331 of 684«‹329330331332333›»

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
Scroll to top